Longeveron to Showcase Innovations at Upcoming Conference
Longeveron to Showcase Innovations at Upcoming Conference
MIAMI, Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company that is pioneering cellular therapies to combat severe and chronic age-related conditions, is set to participate in the Emerging Growth Virtual Conference taking place soon. This yearly conference presents an invaluable opportunity for innovative companies to connect with investors and showcase advancements in their respective fields.
Conference Presentation Details
Longeveron will deliver its presentation on February 19, focusing on its groundbreaking work in regenerative medicine. The time slot for this presentation is 3:10 – 3:20 p.m. ET, where key insights into the company's future directions will be shared.
How to Access the Event
The complete presentation will be available through a live webcast in the "Events and Presentations" section of Longeveron's website. After the conference, the recording will remain accessible for 180 days, allowing more individuals to benefit from the information shared during this significant event.
About Longeveron Inc.
Established with the goal of addressing crucial medical needs, Longeveron is at the forefront of developing innovative regenerative medicines. Its lead investigational product, Lomecel-B™, is based on allogeneic medicinal signaling cells (MSCs) derived from the bone marrow of young, healthy donors. This revolutionary therapy has several mechanisms of action that are pro-vascular, pro-regenerative, and anti-inflammatory, making it suitable for a wide range of diseases.
Current Clinical Focus
Longeveron’s current pipeline targets three significant indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and age-related frailty. The company has received multiple designations from the FDA, including Orphan Drug and Fast Track status for its HLHS program, emphasizing its commitment to advancing treatments that meet critical patient needs.
Contact Information
For inquiries related to the event or the company's developments, individuals are encouraged to reach out via the dedicated questions email. Direct communication with their investor relations team can also shed light on their projects and future milestones.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Frequently Asked Questions
What will Longeveron present at the conference?
Longeveron will showcase its innovative cellular therapies and key advancements in regenerative medicine.
When is Longeveron's presentation scheduled?
The presentation is scheduled for February 19, from 3:10 to 3:20 p.m. ET.
How can I access the conference presentation?
The presentation can be accessed via a live webcast on Longeveron’s website, with a replay available for 180 days post-conference.
What is Lomecel-B™?
Lomecel-B™ is Longeveron’s lead investigational product, designed to harness the properties of medicinal signaling cells for treatment across various conditions.
Who can I contact for more information?
For further inquiries, individuals can email Derek Cole at the provided email address for investor relations.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.